News

13 May 2016
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.
Read more

21 Apr 2016
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).
Read more

25 Nov 2015
Biopta to be acquired by Japanese stem cell company ReproCELL
Biopta is to be acquired by the stem cell and regenerative medicine company ReproCELL. The deal will help Biopta to expands its range of drug discovery services based on human fresh tissues.
Read more

More >

Testimonals

I am very pleased with our cooperation so far; nice data and very good fit to our internal knowledge of the compounds

Senior Scientist, Top 20 European Pharma

We used Biopta because they are able to provide sensitive and accurate information from a wide range of different types of tissue

CEO, UK Biotech

Biopta's human tissue services have played a critical part in our compound selection and have added considerable value to our lead compound

President & Head of R&D, Canadian Biotech
Live chat by BoldChat